BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 6401591)

  • 1. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
    Habs MR; Schmähl D
    Cancer; 1983 Feb; 51(4):606-9. PubMed ID: 6401591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
    Schmähl D; Habs M; Tacchi AM
    Urologe A; 1984 Sep; 23(5):291-6. PubMed ID: 6438859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study.
    Freedman A; Ehrlich RM; Ljung BM
    J Urol; 1984 Sep; 132(3):580-2. PubMed ID: 6433044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells.
    Reuther H; Kohl M; Wildenauer DB
    Arzneimittelforschung; 1986 Apr; 36(4):763-5. PubMed ID: 3087373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
    Brock N; Pohl J
    IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of cyclophosphamide-induced carcinogenesis in the urinary bladder of rats by administration of mesna.
    Schmähl D; Habs MR
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():57-61. PubMed ID: 6414697
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
    Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J
    Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).
    Brock N; Pohl J; Stekar J; Scheef W
    Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1377-87. PubMed ID: 6819957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevention of cyclophosphamide-induced bladder swelling in the rat by I.V. administration of sodium-2-mercaptoethane sulfonate.
    Kedar A; Simpson CL; Williams P; Moore R; Tritsch G; Murphy GP
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):339-48. PubMed ID: 6774389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.
    Mohrmann M; Ansorge S; Schönfeld B; Brandis M
    Pediatr Nephrol; 1994 Aug; 8(4):458-65. PubMed ID: 7524598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat.
    Ormstad K; Uehara N
    FEBS Lett; 1982 Dec; 150(2):354-8. PubMed ID: 6819161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
    Ehrlich RM; Freedman A; Goldsobel AB; Stiehm ER
    J Urol; 1984 May; 131(5):960-2. PubMed ID: 6423841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium 2-mercaptoethane sulfonate protection against cyclophosphamide-induced teratogenicity in rats.
    Slott VL; Hales BF
    Toxicol Appl Pharmacol; 1986 Jan; 82(1):80-6. PubMed ID: 3080822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fate of [14C]-mesna in the rat.
    Shaw IC; Graham MI; Jones MS
    Arzneimittelforschung; 1986 Mar; 36(3):487-9. PubMed ID: 3085684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of Mesna (2-mercaptoethane sulfonate) with the mutagenicity of cyclophosphamide in vitro and in vivo.
    Lähdetie J; Räty R; Sorsa M
    Mutat Res; 1990 Sep; 245(1):27-32. PubMed ID: 2118231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats.
    Ozcan A; Korkmaz A; Oter S; Coskun O
    Arch Toxicol; 2005 Aug; 79(8):461-5. PubMed ID: 15800758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed development of bladder cancer in male SD rats induced with N-nitroso-N-butyl-N-(4-hydroxybutyl)amine following concomitant administration of sodium 2-mercaptoethane sulfonate.
    Berger MR; Schmähl D
    Cancer Lett; 1986 Sep; 32(3):313-21. PubMed ID: 3094932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing.
    Shaw IC; Weeks MS
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):933-5. PubMed ID: 3117563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylcysteine and sodium 2-mercaptoethane sulfonate as sources of urinary thiol groups in the rat.
    Ormstad K; Ohno Y
    Cancer Res; 1984 Sep; 44(9):3797-800. PubMed ID: 6430554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.